Reverse acquisition company Hunter Capital RTO1 announces that Resother Pharma, the company's proposed target company in the reverse acquisition, has reported strong top-line results from the Phase 2a study of RTP-026 in patients with ST-elevation myocardial infarction. This is stated in a press release.The results showed a strong safety and tolerability profile together with encouraging and consistent efficacy signals across several parameters for cardiac function and infarct size. The results constitute a key condition under the previously announced letter of intent regarding the proposed reverse acquisition. This condition has now been met. The parties will therefore continue to advance the proposed transaction in accordance with the letter of intent. Overall, the results provide additional clinical support for the continued development of RTP-026.